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Title: Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: 




Background: Venous thromboembolism (VTE) is common in cancer patients.  However, little 
is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We 
sought to characterize the incidence, associative factors, including whether various 
chemotherapy regiments portend different risk, and impact of VTE on survival in metastatic 
UC/VH patients.  
Methods: Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in 
this multi-center retrospective, international study from 29 academic institutions.  Cumulative 
and 6-month VTE incidence rates were determined.  The association of first-line 
chemotherapy (divided into 6 groups) and other baseline characteristics on VTE were 
analyzed.  Each chemotherapy treatment group and statistically significant baseline clinical 
characteristics were assessed in a multivariate, competing risk regression model.  VTE 
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Results: 1762 patients were eligible for analysis.  There were 144 (8.2%) and 90 (5.1%) 
events cumulative and within the first six months, respectively. VTE rates based on 
chemotherapy group demonstrated no statistical difference when gemcitabine/cisplatin was 
used as the comparator. Non-urothelial histology (SHR: 2.67; 95%CI 1.72-4.16, p<0.001), 
moderate to severe renal dysfunction (SHR: 2.12; 95%CI 1.26-3.59, p=0.005), and 
cardiovascular disease (CVD) or CVD risk factors (SHR: 2.27; 95%CI 1.49-3.45, p=0.001) 
were associated with increased VTE rates.  Overall survival was worse in patients with VTE 
(median 6.0m vs. 10.2m,p<0.001).    
Conclusions: In metastatic UC/VH patients, VTE is common and has a negative impact on 
survival.  We identified multiple associated potential risk factors, although different 
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Cancer patients are at increased risk of developing a venous thromboembolism (VTE).  It is 
now estimated that approximately 20%-30% of first VTE in patients are cancer-associated.1 
Improved survival outcomes across multiple malignancies, increasing use of central venous 
catheters, and better imaging modalities to detect venous thrombosis have led to a rising 
incidence of cancer-associated thrombosis over time.2 Importantly, VTEs have been shown 
to have a negative impact on survival.3 In addition, cancer patients with a VTE have 
increased morbidity from anticoagulation, with a higher risk of recurrent VTE and major 
bleeding compared to non-cancer patients with VTE.4 
Patient-related characteristics such as a high body mass index (BMI), elevated white blood 
cell (WBC) and platelet count, and low hemoglobin have been incorporated into the Khorana 
score, a validated, predictive model of VTE risk in patients who are initiating chemotherapy.5 
When looking at specific cancer primary sites, the most aggressive malignancies, such as 
pancreatic cancer, have tended to have the greatest VTE risk.6  Lastly, there is a mounting 
body of evidence for chemotherapy as an independent risk factor for VTE, with the strongest 
data for cisplatin.7-9 Moreover, some studies have indicated especially high thromboembolic 
rates (arterial and venous) in patients treated with the combination of gemcitabine and 
cisplatin (GC).7, 10-12 
Despite the growing amount of data on cancer-associated thrombosis, there is limited 
literature assessing the incidence and risk factors for VTEs in urothelial carcinoma or variant 
histologies (UC/VH), especially in the metastatic setting.  Additionally, UC/VH have been 
underrepresented in previous VTE studies.  In the patient cohort utilized to develop the 
Khorana score, genitourinary malignancies (excluding prostate cancer) were grouped with 
other primary tumor sites which only represented approximately 10% of the study population, 
yet they are still considered a high-risk primary tumor site and given 1 point in the model.5 
Likewise, in the largest randomized, prospective clinical trial assessing primary 
thromboprophylaxis across multiple solid tumors, bladder cancer only accounted for 2% of 
the patient population.13 Given the dearth of information on VTE in patients with metastatic 
UC/VH, we conducted a retrospective cohort study to better understand the incidence and 
risk factors associated with VTE, whether chemotherapy (in particular the combination of 
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METHODS 
 
Study Design and Patient Population 
 
The Retrospective International Study of Cancers of the Urothelium (RISC) is a multi-center 
study of the management and outcomes of patients with cancers of the urothelial tract with at 
least muscle-invasive disease (clinical T-classification of ≥2).  Baseline characteristics, 
laboratory, pathology, treatment, and outcome data were collected and compiled via a 
secure, password-protected electronic data capture platform from 29 international centers as 
previously described.14 The study was approved by the institutional review board at all 
participating institutions.   
Patients diagnosed with metastatic disease of the bladder, renal pelvis, ureter, and urethra 
from January 1,2000 through December 31,2013 were eligible for analysis. Urothelial, 
adenocarcinoma, micropapillary, sarcomatoid, small cell, and squamous histologies were 
included for analysis. In patients with mixed histology tumors, the predominant histologic 
pattern of the tumor was utilized for categorization.  Patients without a known date of 
diagnosis, date of last follow-up, or VTE data were excluded from the study. First-line 
chemotherapy regimens were subdivided into 6 groups for analysis: 1) GC, 2) gemcitabine 
and carboplatin, 3) cisplatin combination (excluding GC), 4) non-platinum regimens, 5) 
carboplatin or oxaliplatin (excluding gemcitabine and carboplatin), and 6) no chemotherapy.  
Specific chemotherapy regimens within the chemotherapy subgroups are listed in 
supplementary Table 1.  Based on previous data suggesting particularly high rates of 
thromboembolic events with GC, we hypothesized that there would be more VTEs in this 
treatment group when compared to other treatment groups.  Additionally, GC is a commonly 
used regimen for advanced disease, therefore, GC was chosen as the reference for 
comparison to the other chemotherapy treatment groups.15 Other baseline patient, tumor, 
and treatment-related characteristics were assessed for their impact on VTE incidence (see 
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Cumulative and 6-month absolute VTE incidence rates were calculated from the date of 
diagnosis of metastatic disease to the VTE date. Each baseline and treatment-related factor 
was assessed, using competing-risk regressions, for association with the development of 
VTE.  Multiple imputations with chained equations were performed to address any missing 
data.  First-line chemotherapy group and any statistically significant covariates in the 
univariate analysis (P≤ .05) were evaluated in a multivariate, competing risk regression 
model.  Sub-distribution hazard ratios (SHR) were calculated for each factor.   
To assess survival, a nested case-control analysis was performed where VTE patients 
(cases) were matched to non-VTE patients (controls).  Cases and controls were matched 
based on time from date of diagnosis of metastatic disease to date of VTE diagnosis of the 
case, age, gender, race, and whether the patient received chemotherapy.  Patients were also 
matched based on ECOG performance status and presence of liver metastases as these 
factors have been previously demonstrated to be poor prognostic features in patients with 
bladder cancer.16  All attempts were made to match five controls to one case, however, 
because of the number of variables utilized, 5:1 matching could not be achieved for all strata.  
In those cases, the highest degree of matching possible was employed.  Overall survival was 
calculated from the time of the VTE event.  The log-rank test was utilized to compare survival 




Study Population and Patient Characteristics 
 
The RISC database is comprised of 3025 patients.  1912 patients were diagnosed with 
metastatic disease (Figure 1).  Of these, 65 patients were diagnosed prior to January 1, 2000 
and thus excluded from the analysis.  An additional 85 patients were excluded due to missing 
or miscoded date of diagnosis, last follow-up, or VTE data to arrive at a final cohort of 1762 
patients eligible for analysis.  Baseline characteristics of the entire study cohort are outlined 
in Table 1.  The majority of the patients were greater than 65 years of age (59.0%), male 
(77.5%) and white (90.5%).  The predominant histologic subtype was urothelial, representing 
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cancer diagnosis.  Node-positive (any T, N1-N3, M0) and metastatic disease (any T, any N, 
M1) accounted for 14.6% and 22.1%, respectively.  The median number of cycles of first-line 
chemotherapy was four.   
Incidence of Venous Thromboembolism and Association with Clinical Characteristics 
Unadjusted VTE incidence rates based on patient demographics and clinical characteristics 
of the 1762 patients are shown in Table 2.  Altogether, there were 144 VTEs with 90 of them 
occurring in the first 6 months.  The cumulative and 6-month VTE incidence rate was 8.2% 
(95%CI, 6.9%-9.6%) and 5.1% (95%CI, 4.1%-6.2%), respectively.  The cumulative VTE rate, 
when calculated as a function of time, was 7.5 events per 100 person-years.  In the 
univariate analysis, cumulative VTE incidence was statistically significantly increased in 
patients with cardiovascular (CVD) or CVD risk factors (p<0.001), moderate to severe renal 
dysfunction (p=0.001), non-urothelial tumor histology (p<0.001), and those whose primary 
tumor was treated with radiation therapy (p=0.02).  No other clinical characteristics were 
statistically significant. 
 
Incidence of Venous Thromboembolism and First-line chemotherapy 
The cumulative incidence of VTE in patients who received chemotherapy was 9.6% (95%CI, 
8.1%-11.3%).  Unadjusted absolute, cumulative VTE incidence rates based on first-line 
chemotherapy regimen are shown in Table 2.  The absolute cumulative incidence over time 
for each chemotherapy regimen is shown in Figure 2. The highest absolute cumulative VTE 
incidence was seen in patients who received GC at 11.0% (95%CI, 8.2%-14.2%).  
Gemcitabine and carboplatin and cisplatin-containing regimens accounted for an absolute 
cumulative incidence of VTE of 9.8% (95%CI, 6.9%-13.5%) and 6.9% (95%CI, 3.8%-11.4%), 
respectively.  Patients who did not receive chemotherapy had an absolute VTE incidence 
rate of 3.2% (95%CI, 1.7%-5.5%).   
Multivariate Analysis of Venous Thromboembolism Risk 
In addition to chemotherapy treatment group and statistically significant variables in the 
univariate analysis, age, gender, and race were included as demographic variables in the 
multivariate model.  CVD or CVD risk factors (SHR: 2.27; 95%CI 1.49-3.45, p=0.001), 
moderate to severe renal dysfunction (SHR: 2.12; 95%CI 1.26-3.59, p=0.005), and non-
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increased risk of VTE (Table 3).  Patients who were treated with radiation therapy to the 
primary tumor did not have a statistically significantly greater VTE risk in the multivariate 
model (SHR: 1.42; 95%CI 0.83-2.41, p=0.20).  Using GC as the reference, there was no 
statistically significant difference in VTE incidence rates based on chemotherapy regimen.  
However, patients who did not receive systemic chemotherapy had a decreased incidence of 
VTE compared to those treated with GC (SHR: 0.32; 95%CI 0.16-0.61, p=0.001).   
Survival  
There was a statistically significant increase in mortality in patients who had a VTE compared 
to patients without a VTE (p<0.001).  Median survival was 6.0 months (95%CI: 3.1-8.8) from 
time of VTE versus 10.2 months (95%CI: 8.4-12.2) in matched controls (Figure 3). 
DISCUSSION 
Few studies have examined the VTE incidence rate of patients with metastatic UC/VH.  A 
Dutch population-based study demonstrated a 6-month VTE incidence rate of 3.1% in 
bladder or ureteral cancer patients with distant metastases.17 Recently, Sandhu et al. found a 
6.3% 2-year cumulative VTE incidence rate in patients with advanced bladder cancer utilizing 
a state cancer registry that was linked to hospital discharge data.18 In our patient cohort, 
metastatic UC/VH patients had higher cumulative and 6-month VTE incidence rates, 8.2% 
and 5.1% respectively, than these previous studies.  Importantly, the VTE rate seen in our 
analysis is comparable to the most thrombogenic primary tumor sites.  When compared to 
the VTE rate (expressed in VTEs per 1000 person-years) in a systematic review and meta-
analysis of 8 cancer types from 38 studies, the rate in our cohort (75/1000 person-years) was 
only superseded by the VTE rate in pancreatic (102/1000 person-years) and brain cancer 
(116/1000 person-years).6 Consequently, our study supports considering patients with 
metastatic UC/VH at relatively high-risk for VTE. 
Venous thromboembolism has been shown to be independently associated with worse 
overall survival in cancer patients when compared to cancer patients without a VTE.  
Sørensen et al. reported a 1 year overall survival of 12% in cancer patients with VTE 
compared to 36% in matched control cancer patients across a wide range of malignancies.3 
Furthermore, other studies, not specifically in UC/VH, have demonstrated that prognosis is 
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metastatic UC/VH patients who had a VTE compared to those who did not in our analysis is 
consistent with prior studies, and identification of appropriate preventative interventions that 
may improve outcomes is imperative. 
Currently, based on randomized-controlled data, routine primary prophylaxis is not 
recommended in the outpatient oncology setting with the exception of multiple myeloma 
patients on lenalidomide or thalidomide-containing regimens.21 One reason for this 
recommendation is the relatively low frequency of VTEs seen in randomized-control trials 
(RCTs).  Two primary prophylaxis RCTs, PROTECHT and SAVE-ONCO, demonstrated a 
statistically significant decrease in VTE in multiple solid tumors.13, 22 However, the placebo 
arms in PROTECHT and SAVE-ONCO had a VTE rate of only 2.9% and 3.4%, respectively 
at a median duration of treatment of approximately 3.5 months.  Therefore the absolute 
reduction in VTE was too small to justify primary prophylaxis.  The absolute incidence in our 
study (3.4% at 3 months) is similar to the rates seen in PROTECHT and SAVE-ONCO, thus 
it is logical to conclude that primary prophylaxis of all patients with metastatic UC/VH would 
not be recommended.    
We evaluated multiple clinical characteristics to identify a subset of metastatic UC/VH 
patients who might be at particularly high-risk for VTE. An association was found between 
patients with non-urothelial histology, renal dysfunction, or CVD or CVD risk factors and VTE.  
However, the underlying mechanism of these associations has not been clearly elucidated.  
It is likely that non-urothelial histology results in more VTEs, at least in part, because patients 
tend to present with more locally advanced disease when compared to urothelial histology, 
leading to extrinsic compression of the vasculature and venous thrombosis.23 Several large, 
epidemiologic studies have shown a link between CVD or CVD risk factors and renal 
dysfunction with venous clot formation in non-cancer patients.24-26 Patients with CVD or CVD 
risk factors and/or renal dysfunction may be predisposed to VTE through alterations in the 
balance of hemostatic proteins.  A recent case-control study suggested that chronic kidney 
disease patients with a VTE had increased levels of Factor VIII and von Willebrand factor.27 
Additionally, patients with coronary artery disease and peripheral arterial disease have been 
shown to have elevated markers of coagulation, such as fibrinogen and D-dimer, though 
correlation with VTE rates were not assessed in these studies.28, 29 We believe that the 
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validation in an independent cohort.  If validated as risk factors, these features may be used 
in the future to identify a patient population with sufficiently high VTE risk for a primary 
prophylaxis study.  
Numerous studies have suggested that cisplatin increases VTE risk.7-9 Recently, the 
combination of GC has been associated with especially high VTE rates.  Plimack et al. 
presented a vascular (arterial and venous) event rate of 23% in a neoadjuvant study of dose-
dense GC for muscle-invasive bladder cancer, leading to early study closure.30 Thus, we 
were interested in comparing the VTE rates for GC to other chemotherapy regimens in 
patients with metastatic UC/VH.  In our patient cohort, there was no statistical difference in 
VTE risk based on chemotherapy group when compared to GC.  However, our result may 
represent a false-negative as the analysis was underpowered to detect a small difference.  
Interestingly, though not statistically significant, the absolute VTE incidence rate was highest 
in the patients that were treated with GC, with an 11.0% VTE rate.  Conversely, patients 
treated with cisplatin regimens, which did not include gemcitabine, had a VTE rate of 6.9%.  
Moreover, the point estimates of the subdistribution hazard ratios for each of the 
chemotherapy groups in the multivariate analysis were less than 1 when compared to GC. 
This suggests the possibility of gemcitabine increasing VTE risk or a synergistic effect in 
patients treated with GC.  The decreased incidence of VTE seen in patients who did not 
receive chemotherapy may support the role of cytotoxic chemotherapy as a risk factor for 
VTE.  However, this result should be interpreted with caution.  Patients who did not receive 
chemotherapy may have had less intensive surveillance imaging, since there was no reason 
to ascertain treatment response, thereby missing incidental pulmonary emboli. 
There are several limitations to our analysis.  First, our study is limited by the inherent 
confounders and biases associated with any retrospective analysis.  Second, whether a VTE 
was catheter-associated was not consistently captured and therefore not included in the 
analysis.  Also, data was not available on whether patients were already on anticoagulation 
for an alternative indication (e.g. atrial fibrillation).  Furthermore, some of the clinical factors 
were investigator-designated (e.g. moderate to severe renal dysfunction, diabetes, or 
hypertension) as opposed to utilizing established criteria for diagnosis of these conditions.  
We also did not have the percentages of each histologic subtype composing tumors of mixed 
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Lastly, during the era in which the data was captured, clinical trials including agents that may 
increase VTE rates (e.g. bevacizumab, cetuximab) were ongoing and trial participants were 
not excluded from this analysis.10, 11 
Based on our results, patients with metastatic UC/VH should be counseled about their risk of 
VTE and the associated clinical signs and symptoms.  Patients with significantly increased 
risk should be considered for primary prophylaxis in clinical trials designed to enroll a high-
risk population.  Additionally, larger population-based studies should be undertaken to 
validate the clinical risk factors identified in this analysis and further evaluate the impact of 
chemotherapy regimens on VTE risk.  Finally, more intensive investigation of the underlying 
biologic mechanisms is necessary to improve our understanding of the pathogenesis of 
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Figure 1: Flow chart of patient inclusion and exclusion criteria. 
 
Figure 2: Absolute cumulative incidence of venous thromboembolic events based on first-
line chemotherapy regimen.  CTX: chemotherapy.  VTE: venous thromboembolism. 
*Carboplatin and oxaliplatin regimens (excluding gemcitabine and carboplatin) not shown 
due to comparatively smaller sample size, representing 4.3% of the cohort. 
 
Figure 3: Kaplan-Meier survival curve of patients who had a venous thromboembolic event 
(VTE) and no venous thromboembolic event (No VTE).  P-value is a result of the log-rank 



































Table 1: Patient Characteristics  
 
N (%) 
Total 1762 (100) 
Age   
<40 15 (0.9) 
40-64 683 (38.8) 
>65 1039 (59.0) 
Unknown 25 (1.4) 
Gender   
Male 1365 (77.5) 
Female 390 (22.1) 
Unknown 7 (0.4) 
Race   
White 1595 (90.5) 
Non-white 157 (8.9) 
Unknown 10 (0.6) 
Primary Tumor Location 
 
Bladder 1462 (83.0) 
Other (renal pelvis, ureter, or urethra) 265 (15.0) 
Unknown 35 (2.0) 
Histology 
 
Urothelial 1525 (86.5) 
Non-urothelial  183 (10.4) 
Unknown 54 (3.1) 
Primary Treatment   
Surgery* 593 (33.7) 
Surgery* with perioperative chemotherapy 422 (24.0) 
Radiation 117 (6.6) 
Radiation with concurrent chemotherapy 89 (5.1) 
None/Unknown 541 (30.7) 
* Encompasses patients who underwent a radical cystectomy, nephroureterectomy, nephrectomy, ureterectomy, or urethrectomy as their 


















































Total 144/1762 7.5 (6.4-8.8) 8.2 (6.9-9.6) -- 
Age     
<40 1/15 3.6 (0.5-25.7) 6.7 (0.2-31.9) 0.10‡ 
40-64 65/683 8.0 (6.3-10.2) 9.5 (7.4-12.0)  
>65 77/1039 7.3 (5.8-9.1) 7.4 (5.9-9.2)  
Unknown 1/25 4.2 (0.6-30.1) 4.0 (0.1-20.4)  
Gender     
Male 108/1365 7.2 (6.0-8.7) 7.9 (6.5-9.5) 0.23 
Female 36/390 8.8 (6.4-12.2) 9.2 (6.5-12.6) ref 
Unknown 0/7 0.0 (…)   0.0 (0.0-41.0)^ -- 
Race     
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Non-white 15/142 9.7 (5.8-16.1) 9.6 (5.4-15.3) 0.20 
Unknown 2/10 18.1 (4.5-72.4) 20 (2.5-55.6) -- 




≤11,000 93/949 7.7 (6.3-9.4) 9.8 (8.0-11.9) ref 
>11,000 21/222 9.9 (6.5-15.2) 9.5 (6.0-14.1) 0.61 
Unknown 30/591 6.1 (4.2-8.7) 5.1 (3.5-7.2) -- 




<350,000 78/804 7.6 (6.1-9.4) 9.7 (7.7-12.0) ref 
≥350,000 36/352 9.8 (7.0-13.5) 10.2 (7.3-13.9) 0.62 





<10  20/171 13.5 (8.7-21.0) 11.7 (7.3-17.5) 0.37 
≥10  95/984 7.6 (6.3-9.3) 9.7 (7.9-11.7) ref 
Unknown 29/607 5.5 (3.8-7.9) 4.8 (3.2-6.8) -- 




<35 99/907 9.4 (7.7-11.4) 10.9 (9.0-13.1) ref 
≥35 6/56 6.1 (2.8-13.7) 10.7 (4.0-21.9) 0.99 
Unknown 39/799 5.1 (3.7-7.0) 4.9 (3.5-6.6) -- 




No 48/794 4.8 (3.6-6.4) 6.0 (4.5-7.9) ref 
Yes 96/968 10.4 (8.5-12.7) 9.9 (8.1-12.0) <0.001 




No 122/1605 6.9 (5.8-8.2) 7.6 (6.4-9.0) ref 
Yes 22/157 14.6 (9.6-22.2) 14.0 (9.0-20.4) 0.001 




0 29/345 5.2 (3.6-7.6) 8.4 (5.7-11.8) ref 
1 63/526 9.9 (7.8-12.7) 12 (9.3-15.1) 0.22 
2+ 16/193 11.9 (7.3-19.5) 8.3 (4.8-13.1) 0.78 
Unknown 36/698 6.0 (4.3-8.3) 5.2 (3.6-7.1) -- 




Bladder 121/1462 7.9 (6.6-9.4) 8.3 (6.9-9.8) ref 
Other (renal pelvis, ureter, or urethra) 21/265 6.1 (4.0-9.3) 7.9 (5.0-11.9) 0.58 





Urothelial 105/1525 6.2 (5.1-7.5) 6.9 (5.7-8.3) ref 









































**P-values obtained with univariate competing-risk regressions using the imputed dataset. Univariate regressions were run to assess for 
significance and determine inclusion in the final multivariate model.  The p-values calculated are based on absolute VTE incidence rates. 
‡Univariate analysis on age performed with age as a continuous variable. 
^One-sided, 97.5% confidence interval. 
┼CVD = cardiovascular disease; CVD encompasses coronary artery disease, peripheral vascular disease, a history of myocardial 
infarction, or a cerebrovascular accident; CVD risk factors analyzed include diabetes mellitus, hypertension, and hyperlipidemia.  
┴Investigator-designated moderate to severe renal dysfunction. 
¶76% received methotrexate, vinblastine, doxorubicin, cisplatin (MVAC). 
#Several additional variables were analyzed and not found to be significant in the univariate analysis, including albumin, presence of lymph 
node metastases, history of VTE, surgery within 2 months of diagnosis of metastatic disease and perioperative chemotherapy, and number 

















No 119/1421 7.3 (6.1-8.7) 8.4 (7.0-9.9) ref 
Yes 24/324 9.1 (6.1-13.6) 7.4 (4.8-10.8) 0.66 
Unknown 1/17 4.4 (0.6-31.5) 5.9 (0.1-28.7) -- 




No 113/1450 6.9 (5.8-8.3) 7.8 (6.5-9.3) ref 
Yes 23/206 14.1 (9.3-21.2) 11.2 (7.2-16.3) 0.02 
Unknown 8/106 6.7 (3.3-13.3) 7.5 (3.3-14.3) -- 
First-line chemotherapy     
Gemcitabine and cisplatin (GC) 50/456 7.7 (5.8-10.2) 11.0 (8.2-14.2) ref 
Gemcitabine and carboplatin 34/346 9.2 (6.6-12.9) 9.8 (6.9-13.5) 0.81 
Cisplatin combination (excluding GC)¶ 14/202 4.7 (2.8-7.9) 6.9 (3.8-11.4) 0.12 
Non-platinum based 22/258 8.1 (5.4-12.4) 8.5 (5.4-12.6) 0.67 
Carboplatin or oxaliplatin 8/75 9.4 (4.7-18.7) 10.7 (4.7-19.9) 0.99 
No chemotherapy 13/403 5.6 (3.2-9.6) 3.2 (1.7-5.5) 0.008 




































Table 3: Multivariate, competing risk regression analysis of thromboembolic risk based on 
clinical characteristics 
 SHR 95% CI p-value 
CVD or CVD risk factors┼    
No  1.0 ref ref 
Yes 2.27 1.49-3.45 0.001 
Moderate to severe renal dysfunction┴    
No  1.0 ref ref 
Yes 2.12 1.26-3.59 0.005 
Histology    
Urothelial 1.0 ref ref 
Non-urothelial 2.67 1.72-4.16 <0.001 
Primary tumor radiation therapy    
No 1.0 ref ref 
Yes 1.42 0.83-2.41 0.20 
First-line chemotherapy*    
Gemcitabine and Cisplatin (GC) 1.0 ref ref 
Gemcitabine and Carboplatin 0.86 0.53-1.39 0.53 
Cisplatin combination (excluding GC)
 









































┼CVD = cardiovascular disease; CVD encompasses coronary artery disease, peripheral vascular disease, a history of myocardial   
infarction, or a cerebrovascular accident; CVD risk factors analyzed include diabetes mellitus, hypertension, and hyperlipidemia.  
       ┴Investigator-designated moderate to severe renal dysfunction 
       * Unknown = 22 (3 events) 
       SHR= subdistribution hazard ratio 
 
 
Non-platinum regimen 0.71 0.41-1.21 0.21 
Carboplatin or Oxaliplatin 0.75 0.33-1.72 0.50 





















































3025 Patients in database  
1762 Patients eligible for analysis 
    65 Diagnosis prior to Jan. 1, 2000 
    85 Missing or miscoded data  
																						 
   1113 Without metastatic disease 

















Figure 2: Absolute cumulative incidence of venous thromboembolic events based on 






















Figure 3: Kaplan-Meier survival curve of patients who had a venous thromboembolism 






OS: 6.0m (VTE) vs. 10.2m (no VTE); p<0.001 
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